# Recanalization Rate of Acute DVT

> **NCT06145269** · EARLY_PHASE1 · UNKNOWN · sponsor: **Assiut University** · enrollment: 100 (estimated)

## Conditions studied

- Acute DVT of Lower Extremity

## Interventions

- **DRUG:** New oral anticoagulant (rivaroxaban) and Marevan (warfarin)

## Key facts

- **NCT ID:** NCT06145269
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145269, "Recanalization Rate of Acute DVT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06145269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*